Clinical Trial Update: Silymarin in NAFLD [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of silymarin in non-alcoholic fatty liver disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: University Hospital Rijeka | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 4 | Status: WITHDRAWN